Intel Drops 29% in One Session, Leading All Losers on October 30

As seen on the 24/7 Wall St. homepage on October 30, 2026.

Biggest movers · At the close 4:11pm ET

Gainers

REGNRegeneron$926.96+13.2%
AZNAstraZeneca$186.4+6.9%
SPOTSpotify$593.99+6.6%
TMUST-Mobile$156.39+6.2%
IMOImperial Oil$138.4+5.8%

Losers

INTCIntel$65.12-29.3%
APPSDigital Turbine$8.9-15.8%
SNDKSanDisk$1,149.86-13.6%
AAOIApplied Optoelectronics$68.99-12.9%
COHRCoherent$209.16-11.8%

Intel closed down 29.27%, the widest single-session move across 380 priority names. Regeneron led the other direction, with chip and optics names filling out the downside.

Continue ReadingShow less

Intel's 29.27% single-session decline was the largest move, in either direction, among the 380 priority names tracked at the October 30 close.

Chip and optics names filled out the bottom of the leaderboard, including SanDisk, Applied Optoelectronics, Coherent and Digital Turbine.

Sources

Mentioned: INTC, REGN, AZN, SPOT, TMUS, SNDK, COHR, AAOI

Related Market Updates

Biggest movers · On the open 9:50am ET

Gainers

REGNRegeneron$914.2+11.7%
AZNAstraZeneca$186.72+7.1%
TAKTakeda Pharmaceutical$21.21+6.0%
GILDGilead Sciences$174.95+5.6%
MDLZMondelez International$65.63+5.0%

Losers

INTCIntel$65.27-29.1%
APPSDigital Turbine$9.26-12.4%
MSTRStrategy$125.22-11.6%
DOCNDigitalOcean$89.25-10.7%
DDOGDatadog$238.8-10.2%

Intel opened down 29%, a one-day drop of a size this name almost never posts, while the top of the board belongs entirely to pharma, led by Regeneron. Four of the five biggest decliners fell by double digits.

SNY Sanofi

Q3 2026

8:49am ET

EPS

$3.97

est $1.51 +162.8%

Revenue

$16.15B

est $13.28B +21.7%

Dupixent sales jumped 34.8% to $6.36 billion, beating expectations and lifting full-year guidance. Management is already spending the windfall, expanding the Regeneron alliance to protect earnings through Dupixent's eventual loss of exclusivity.

AZN AstraZeneca

Q3 2026

7:36am ET

EPS

$2.79

est $1.15 +143.5%

Revenue

$16.21B

est $16.00B +1.3%

Oncology revenue rose 17%, more than absorbing a 25% drop in Farxiga after US generics arrived, and AstraZeneca still beat EPS expectations. Management reaffirmed full-year guidance and pointed to 2027 readouts.

Earnings · 2026 Q3 Pascal Soriot CEO

7:36am ET

We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars.

Soriot is putting a dollar figure on AstraZeneca's 2027 catalyst calendar, and it is double what this year's dozen Phase III wins carry. For a $270 billion drugmaker, the pipeline math is now the whole investment case.

REGN Regeneron

Q3 2026

6:50am ET

EPS

$20.07

est $16.19 +23.9%

Revenue

$5.12B

est $4.56B +12.1%

Collaboration revenue jumped 68% to $2.72 billion on record Dupixent sales, with both lines beating expectations. Full-year non-GAAP gross margin guidance moved to roughly 86%.

SNDK SanDisk

Q1 2027

Oct 29, 4:13pm ET

EPS

$49.51

est $46.27 +7.0%

Revenue

$11.03B

est $10.68B +3.3%

Data center revenue of $4.80 billion jumped 61% sequentially, the sixth straight quarter SanDisk has beaten expectations as AI storage demand reprices NAND. December quarter guidance of $12.2 billion to $12.6 billion says the ramp is not done, and an 8-for-1 split lands November 19.

INTC Intel

Q3 2026

Oct 29, 4:08pm ET

EPS

$0.52

est $0.40 +31.6%

Revenue

$16.51B

est $16.47B +0.2%

Data Center and AI revenue jumped 78% to $7.32 billion, carrying the quarter past expectations. The catch is Q4 guidance of $15.0 billion to $16.0 billion, a sequential step down, with management warning the PC slowdown runs at least through the first half of 2027.

INTC Intel

Regular session

Oct 29, 3:15pm ET

$91.30

-4.43% open $95.53

A 4.43% drop to $91.30 takes roughly $21 billion off Intel's $481.9 billion market cap in a single session. Keep an eye on whether the $91 handle holds into the close.

Biggest movers · At the close Oct 28, 4:11pm ET

Gainers

VRTVertiv$243.72+16.9%
SKHYSK hynix$164.45+13.1%
ORCLOracle$145.27+11.3%
FNFabrinet$368.47+7.4%
SNDKSanDisk$1,400.83+7.4%

Losers

BKRBaker Hughes$54.78-7.2%
BSXBoston Scientific$42.25-6.3%
SANBanco Santander$11.71-6.1%
FTNTFortinet$174.37-5.8%
GRMNGarmin$272.79-5.7%

Vertiv closed up 16.86% at $243.72, the widest single-name gain across our 382-stock priority list today.

TMUS T-Mobile

Q3 2026

Oct 28, 4:02pm ET

EPS

$3.22

est $2.91 +10.6%

Revenue

$23.58B

est $23.14B +1.9%

The SpaceX scare hasn't dented the cash engine: T-Mobile topped expectations on both lines and lifted the floor on its 2026 adjusted free cash flow guidance to $18.7 billion to $18.8 billion.

Biggest movers · On the open Oct 28, 9:50am ET

Gainers

VRTVertiv$232.61+11.5%
SKHYSK hynix$160.16+10.2%
SNDKSanDisk$1,380.36+5.8%
MUMicron Technology$976.34+5.1%
APHAmphenol$82.08+5.0%

Losers

BSXBoston Scientific$40.6-9.9%
TERTeradyne$298.64-7.7%
TELTE Connectivity$211.87-6.0%
GSKGSK$48.05-5.7%
STXSeagate Technology$633.24-5.2%

Vertiv's 11.5% jump tops the open, and the spread to Boston Scientific at the bottom runs better than 21 points. Hardware names fill both lists, so owning the sector is no guarantee of being on the right side today.